Neuroblastoma

Advances in Pediatrics

Volumn 58, Issue 1, 2011, Pages 297-311

  Colon, Nadja C ^a   Chung, Dai H ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959997104     PISSN: 00653101     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yapd.2011.03.011     Document Type: Review

References (47)

1. Park J.R., Eggert A., Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010, 24:65-86.
2. Maris J.M. Recent advances in neuroblastoma. N Engl J Med 2010, 362:2202-2211.
3. Esiashvili N., Anderson C., Katzenstein H.M. Neuroblastoma. Curr Probl Cancer 2009, 33:333-360.
4. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003, 3:203-216.
5. London W.B., Matthay K.K., Ambros P.F., et al. Clinical and biological features predictive of survival after relapse of neuroblastoma: a study from the International Neuroblastoma (NB) Risk Group (INRG) Database. J Clin Oncol 2010, 28:9518.
6. Kushner B.H. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med 2004, 45:1172-1188.
7. Haase G.M., LaQuaglia M.P. Neuroblastoma. Operative pediatric surgery 2003, 1181-1192. McGraw-Hill, New York. M.M. Ziegler, R.G. Azizkhan, T.R. Weber (Eds.).
8. Ishola T.A., Chung D.H. Neuroblastoma. Surg Oncol 2007, 16:149-156.
9. Darnell R.B., Posner J.B. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003, 349:1543-1554.
10. Goto S., Umehara S., Gerbing R.B., et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001, 92:2699-2708.
11. Janoueix-Lerosey I., Schleiermacher G., Delattre O. Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene 2010, 29:1566-1579.
12. Maris J.M. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr 2005, 17:7-13.
13. Monclair T., Brodeur G.M., Ambros P.F., et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009, 27:298-303.
14. Cohn S.L., Pearson A.D., London W.B., et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009, 27:289-297.
15. Kim S., Chung D.H. Pediatric solid malignancies: neuroblastoma and Wilms' tumor. Surg Clin North Am 2006, 86:469-487. xi.
16. Van Roy N., De Preter K., Hoebeeck J., et al. The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy. Genome Med 2009, 1:74.
17. Fujita T., Igarashi J., Okawa E.R., et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 2008, 100:940-949.
18. Vandesompele J., Baudis M., De Preter K., et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 2005, 23:2280-2299.
19. Kelleher F.C., McDermott R. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. Eur J Cancer 2010, 46:2357-2368.
20. Modak S., Cheung N.K. Neuroblastoma: therapeutic strategies for a clinical enigma. Cancer Treat Rev 2010, 36:307-317.
21. Bell E., Chen L., Liu T., et al. MYCN oncoprotein targets and their therapeutic potential. Cancer Lett 2010, 293:144-157.
22. Taggart D.R., Han M.M., Quach A., et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol 2009, 27:5343-5349.
23. Peaston A.E., Gardaneh M., Franco A.V., et al. MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells. Br J Cancer 2001, 85:1564-1571.
24. Yalcin B., Kremer L.C., Caron H.N., et al. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev 2010, 5. CD006301.
25. Reynolds C.P., Matthay K.K., Villablanca J.G., et al. Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003, 197:185-192.
26. Kang T.I., Brophy P., Hickeson M., et al. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma. J Pediatr Hematol Oncol 2003, 25:769-773.
27. Matthay K.K., Yanik G., Messina J., et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007, 25:1054-1060.
28. Wagner L.M., Danks M.K. New therapeutic targets for the treatment of high-risk neuroblastoma. J Cell Biochem 2009, 107:46-57.
29. Wu J.M., DiPietrantonio A.M., Hsieh T.C. Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis 2001, 6:377-388.
30. Yip C.K., Murata K., Walz T., et al. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell 2010, 38:768-774.
31. Coulter D.W., Blatt J., D'Ercole A.J., et al. IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth. Anticancer Res 2008, 28:1509-1516.
32. Moore A.S., Blagg J., Linardopoulos S., et al. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia 2010, 24:671-678.
33. Gorgun G., Calabrese E., Hideshima T., et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010, 115:5202-5213.
34. Brodeur G.M., Minturn J.E., Ho R., et al. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res 2009, 15:3244-3250.
35. Thiele C.J., Li Z., McKee A.E. On Trk-the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin Cancer Res 2009, 15:5962-5967.
36. Kushner B.H., Kramer K., Cheung N.K. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 2001, 19:4189-4194.
37. Ozkaynak M.F., Sondel P.M., Krailo M.D., et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol 2000, 18:4077-4085.
38. Yu A.L., Gilman A.L., Ozkaynak M.F., et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010, 363:1324-1334.
39. Shusterman S., Grupp S.A., Barr R., et al. The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res 2001, 7:977-984.
40. Barbieri E., Mehta P., Chen Z., et al. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther 2006, 5:2358-2365.
41. Slack A., Lozano G., Shohet J.M. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis. Cancer Lett 2005, 228:21-27.
42. Van Maerken T., Speleman F., Vermeulen J., et al. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res 2006, 66:9646-9655.
43. Casero R.A., Marton L.J. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 2007, 6:373-390.
44. Hogarty M.D., Norris M.D., Davis K., et al. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 2008, 68:9735-9745.
45. Kim S., Hu W., Kelly D.R., et al. Gastrin-releasing peptide is a growth factor for human neuroblastomas. Ann Surg 2002, 235:621-629. [discussion: 629-30].
46. Kang J., Ishola T.A., Baregamian N., et al. Bombesin induces angiogenesis and neuroblastoma growth. Cancer Lett 2007, 253:273-281.
47. Qiao J., Kang J., Ishola T.A., et al. Gastrin-releasing peptide receptor silencing suppresses the tumorigenesis and metastatic potential of neuroblastoma. Proc Natl Acad Sci U S A 2008, 105:12891-12896.